About Salubris Biotherapeutics
Salubris Biotherapeutics is a company based in Gaithersburg (United States) founded in 2016 by John Li. Salubris Biotherapeutics has raised $35 million across 1 funding round. The company has 1 employees as of December 31, 2020. Salubris Biotherapeutics offers products and services including Antibody Therapeutics and Protein-Based Therapeutics.
- Headquarter Gaithersburg, United States
- Employees 1 as on 31 Dec, 2020
- Founders John Li
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Salubris
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$35 M (USD)
in 1 rounds
-
Latest Funding Round
$35 M (USD), Series A
Apr 23, 2024
-
Investors
Not available
-
Employee Count
1
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Salubris Biotherapeutics
Salubris Biotherapeutics offers a comprehensive portfolio of products and services, including Antibody Therapeutics and Protein-Based Therapeutics.
Develops treatments targeting cardiovascular diseases.
Advances therapies for oncology and cancer needs.
People of Salubris Biotherapeutics
Unlock access to complete
Funding Insights of Salubris Biotherapeutics
Salubris Biotherapeutics has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series A round of $35 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Salubris Biotherapeutics
Investment portfolio details for Salubris Biotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Salubris Biotherapeutics
Detailed financials for Salubris Biotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Salubris Biotherapeutics Comparisons
Peer comparison for Salubris Biotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Salubris Biotherapeutics
Detailed competitors of Salubris Biotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Salubris Biotherapeutics
Complete news archive for Salubris Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Salubris Biotherapeutics
Salubris Biotherapeutics was founded in 2016 and raised its 1st funding round 8 years after it was founded.
Salubris Biotherapeutics is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
John Li is the current CEO of Salubris Biotherapeutics. They have also founded this company.
Salubris Biotherapeutics is a funded company, having raised a total of $35M across 1 funding round to date.
As of Dec 31, 2020, the latest employee count at Salubris Biotherapeutics is 1.
Salubris Biotherapeutics was founded in 2016 in Gaithersburg, United States, as a biotechnology firm affiliated with Shenzhen Salubris Pharmaceuticals. Antibody and protein-based therapeutics are developed by the company for cancer, cardiovascular, and metabolic diseases. The lead candidate remains undisclosed and is in the preclinical stage, targeted at cancer treatment. Operations focus on advancing these biologics through research and development in the biopharmaceutical sector.
Salubris Biotherapeutics offers Antibody Therapeutics and Protein-Based Therapeutics.